GCP Infrastructure Investments Limited
("GCP Infra" or the "Company")
Additional Listing and Total Voting Rights
4 June 2019
In conformity with the FCA's Disclosure Guidance and Transparency Rules, GCP Infra, the only UK listed fund focused primarily on investments in UK infrastructure debt, today announces that further to the Company's announcement on 24 May 2019, 276,715 ordinary shares have been admitted to the Premium Listing segment of the Official List of the UK Listing Authority and dealings have commended on the London Stock Exchange's Main Market for listed securities at 8.00 a.m. today.
As at 4 June 2019, the Company's issued share capital consists of 877,432,302 Ordinary shares of £0.01 each with voting rights.
The above figure of 877,432,302 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, GCP Infra, under the FCA's Disclosure Guidance and Transparency Rules.
For further information please contact:
Gravis Capital Management Limited
Dion Di Miceli
+44 (0) 20 3405 8500
Stifel Nicolaus Europe Limited
Gaudi Le Roux
+44 (0)20 7710 7600
+44 (0)20 7466 5000
Notes to the Editor
About GCP Infra
GCP Infra is a closed-ended investment company and FTSE-250 constituent whose shares are traded on the main market of the London Stock Exchange. Its objective is to provide shareholders with regular, sustained, long-term distribution and to preserve capital over the long term by generating exposure to UK infrastructure debt and related and/or similar assets. The Company primarily targets investments in infrastructure projects, with long term, public sector-backed, availability-based revenues. Where possible, investments are structured to benefit from partial inflation-protection. GCP Infra is advised by Gravis Capital Management.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.